MODIFIED PEPTIDE THAT REDUCES PAIN IN PERIPHERAL NEUROPATHY

摘要

The all D TTNYT peptide exhibits potent antagonism for both CCR2 (ICso 4.2pM) and CCR5 (ICso ?.18??) in monocyte chemotaxis. Oral administration of All D TTNYT (0.05-1 mg/kg) for 7 days fully prevents mechanical allodynia and inhibits the development of thermal hyperalgesia following partial ligation of the sciatic nerve in rats. Administration for additional 5 days (0.2-1 mg/kg) reverses already established hypersensitivity. The all D TTNYT reduces spinal microglial activation, monocyte infiltration, and to inhibit inflammatory responses evoked by peripheral nerve injury that cause chronic pain. Our findings suggests that all O TTNYT peptide is a dual CCR2/CCR5 antagonist and has therefore the potential for broad clinical use in neuropathic pain treatment.